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Abstract 
This paper describes the preparation of iron oxide nanoparticles, surface of which 
was coated with extremely high immobilization stability and relatively higher density of 
poly(ethylene glycol) (PEG), which are referred to as PEG protected iron oxide 
nanoparticles (PEG-PIONs). The PEG-PIONs were obtained through alkali 
coprecipitation of iron salts in the presence of the PEG-poly(4-vinylbenzylphosphonate) 
block copolymer (PEG-b-PVBP). In this system, PEG-b-PVBP served as a surface 
coating that was bound to the iron oxide surface via multipoint anchoring of the 
phosphonate groups in the PVBP segment of PEG-b-PVBP. The binding of 
PEG-b-PVBP onto the iron oxide nanoparticle surface and the subsequent formation of 
a PEG brush layer were proved by FT-IR, zeta potential, and thermogravimetric 
measurements. The surface PEG-chain density of the PEG-PIONs varied depending on 
the [PEG-b-PVBP]/[iron salts] feed-weight ratio in the coprecipitation reaction. 
PEG-PIONs prepared at an optimal feed-weight ratio in this study showed a high 
surface PEG-chain surface density (≈ 0.8 chains nm-2) and small hydrodynamic 
diameter (<50 nm). Furthermore, these PEG-PIONs could be dispersed in 
phosphate-buffered saline (PBS) that contains 10% serum without any change in their 
hydrodynamic diameters over a period of one week, indicating that PEG-PIONs would 
provide high dispersion stability under in vivo physiological conditions as well as 
excellent anti-biofouling properties. In fact we have confirmed the prolong blood 
circulation time and facilitate tumor accumulation (more than 15 % ID g-1 tumor) of 
PEG-PIONs without the aid of any target ligand in mouse tumor models. The majority 
of the PEG-PIONs accumulated in the tumor by 96 h after administration, whereas 
those in normal tissues were smoothly eliminated by 96 h, proving the enhancement of 
tumor selectivity in the PEG-PION localization. The results obtained here strongly 
suggest that originally synthesized PEG-b-PVBP, having multipoint anchoring character 
by the phosphonate groups, is rational design for improvement in nanoparticle as in vivo 
application.  Two major points, viz., extremely stable anchoring character and dense 
PEG chains tethered on the nanoparticle surface, worked simultaneously to become 
PEG-PIONs as an ideal biomedical devices intact for prolonged periods in harsh 
biological environments. 
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1. Introduction 
A major limitation of nanoparticle-based biodevices for in vivo applications 
(including drug delivery and imaging) is their nonspecific biodistribution. In general, 
when the nanoparticles are administered in the bloodstream, they are rapidly bound by 
plasma components including serum proteins, which results in the formation of 
aggregates that are rapidly eliminated from the bloodstream because of uptake by 
reticular endothelial systems (RES) such as macrophages in the liver and spleen [1,2]. 
Thus, the nanoparticles are nonspecifically accumulated in the liver and spleen before 
reaching their target site. Several studies have already revealed that the in vivo behavior 
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of nanoparticles depends greatly on their morphology and surface properties [3-5]. In 
order to improve the blood circulation behavior as well as the in vivo distribution of 
nanoparticles, their sizes have to be controlled within the range 10−50 nm. Furthermore, 
the nanoparticle surface should be engineered to maximally reduce the nonspecific 
interactions with plasma proteins, since the RES-mediated rapid clearance of 
nanoparticles is triggered by the adsorption of these proteins on their surfaces. 
In this regard, a common approach is the introduction of poly(ethylene glycol) (PEG) 
chains with an optimal molecular weight onto the nanoparticle surface (so-called 
“PEGylation”). PEG is a hydrophilic, nonionic, and biocompatible polymer, which 
stabilizes the nanoparticles in aqueous media mainly through the effects of steric 
repulsion [6]. Nowadays, PEGylation is regarded as one of the most appropriate 
methodologies for reducing nonspecific interactions with various biological components 
and improving the blood circulation of nanoparticles. It has also been recognized that a 
high PEG-chain density on the surface is essential for the effective suppression of these 
nonspecific interactions with biological components [7-10]. Thus, despite the 
prevalence of the PEGylation of nanoparticles, there is a need for further improvement 
in the surface immobilization density of the PEG chains, as well as in their binding 
stability to the nanoparticle surface, so that the PEGylated nanoparticles will remain 
intact in harsh biological environments over long periods. 
Previously, we have examined the facile and effective PEGylation of various 
nanoparticles using PEG-based hydrophilic block copolymers [11-14]. The basic design 
of our polymeric coatings, which combines the intramolecular microphase separation 
property and the multipoint anchoring effect, has been proved useful for improving the 
dispersion stability of various nanoparticles in physiological media. For instance, we 
demonstrated that the PEG-poly[(2-N,N-dimethylamino)ethyl methacrylate] block 
copolymer (PEG-b-PAMA) effectively binds to the surface of gold nanoparticles 
(GNPs) through multipoint coordination of the tertiary amino groups of the PAMA 
segment [12,13]. The dense and stable PEG brush layer means that the resulting 
PEGylated GNPs can maintain their dispersed state under harsh conditions (e.g., high 
salt concentrations, broad pH range) for long periods of time. In addition, the 
PEGylated GNPs showed high dispersion stability even in the 95% human serum [13]. 
We also demonstrated the stabilization of Y2O3 nanoparticles (YNPs) doped with Er 
ions using the PEG-poly(acrylic acid) block copolymer (PEG-b-PAAc). PEG-b-PAAc 
bound to the YNP surface through multipoint anchoring between the PAAc segment 
and the YNP surface, resulting in the formation of a PEG brush layer on the surface of 
the YNP. The dispersion stability of these YNPs in physiological saline was 
significantly improved by surface treatment with PEG-b-PAAc [14]. 
In this study, we focused our attention on iron oxide nanoparticles (IONs). Over the 
past two decades, IONs have received a lot of attention because of their high potential 
for use in various biomedical applications such as MR imaging, drug delivery, and 
magnetic hyperthermia (including magnetic thermo-ablation)[15-17]. Although there 
have been large numbers of attempts to PEGylate IONs already [18-32], the 
improvement of the surface PEG brush density, as well as the PEG brush stability, 
remains a challenge. Recently, Jeong and Jon et al. reported the application of the 
poly(3-(trimethoxysilyl)propyl methacrylate)-(poly(ethylene glycol methyl ether 
methacrylate)) random copolymer for the coating of IONs [29,30]. The trimethoxysilyl 
groups within this polymer can bind to the ION surface through the formation of 
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Fe−O−Si bonds or crosslinking with each other under heat treatment. This results in the 
formation of a robust silica network on the ION surface. A stable PEG brush layer was 
formed on the ION surface by treatment with this polymer. The resulting IONs formed a 
stable dispersion under physiological conditions, and after intravenous administration, 
they accumulated effectively in the tumor without the aid of a targeting ligand. More 
recently, a novel approach has been developed to obtain highly PEGylated small IONs. 
This approach is based on the controlled deposition of a thin layer of gold on the ION 
surface following PEG−SH immobilization through Au−S bond formation [31,32]. 
However, such methods include complicated and/or multistep procedures for the 
preparation of PEGylated IONs with adequate stability.  
Here, we adopted our surface-coating strategy, which utilizes PEG-based hydrophilic 
block copolymers to prepare densely and stably PEGylated IONs. In this approach, we 
employed the PEG-poly(4-vinylbenzylphosphonate) block copolymer (PEG-b-PVBP, 
Scheme 1a). The phosphonate group was chosen because of its well-known ability to 
bind to various metal oxides including iron oxides [33-38]. The PVBP segment in 
PEG-b-PVBP was anticipated to bind strongly onto the ION surface through multipoint 
anchoring. In addition, the main-chain structure of the PVBP segment consisting of 
polystyrene would enhance the anchoring of the PVBP segment onto the ION surface 
because of its hydrophobic nature, which would prevent the detachment of the 
surface-bound PEG-b-PVBP under harsh biological conditions. IONs covered with 
PEG-b-PVBP (PEG-PIONs) were prepared through the conventional alkali 
coprecipitation of iron salts in the presence of varying amounts of PEG-b-PVBP. 
Structural and physicochemical characterizations of the PEG-PIONs were carried out 
using various analytical techniques. The relationship between the surface PEG-chain 
density and the dispersion stability of the PEG-PIONs under physiological conditions 
was examined using dynamic light scattering (DLS). Finally, the in vivo distribution of 
the PEG-PIONs after intravenous administration to tumor-bearing mice was assessed by 
inductively coupled plasma mass spectrometry (ICP-MS).  
 
 
2. Materials and methods 
 
2.1. Materials 
Materials and synthesis of PEG-b-PVBP[39] are described in Supporting Information. 
The number-averaged molecular weight (Mn) of PEG segment was 5,000 g mol-1, and 
the number of repeating units (n) of PVBP segment was 15. 
 
2.2. Measurements 
Measurements are described in Supporting Information. 
 
2.3. Preparation of iron oxide nanoparticles covered with PEG-b-PVBP 
(PEG-PIONs) 
FeCl2·4H2O (138 mg, 0.7 mmol) and FeCl3·6H2O (409 mg, 1.5 mmol) were weighted 
into a pear-shaped flask and dissolved in 3 mL of water. PEG-b-PVBP solution (2 mL 
in water) was added to this solution and the resulting mixture was stirred for 5 min. 
NH4OH (25% v/v in H2O, 11.3 mL) was added with vigorous stirring. The reaction 
mixture was allowed to stir at room temperature for 2 h, and then dialyzed (MWCO 
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20,000) against 2 L of water. The dialysate water was changed after 2, 6, and 12 h, 
respectively. Unbound (free) PEG-b-PVBP was removed by ultrafiltration (PSF 
membrane, MWCO: 200,000). Four types of PEG-PION were prepared by varying the 
feed-weight ratio between PEG-b-PVBP and iron salts (see Table 1). The resulting 
PEG-PIONs were dispersed in either deionized water or physiological saline, and were 
stored at 4 °C before use.  
 
2.4. Cell culture and in vitro cell cytotoxicity assay 
C-26 cells were maintained as an adherent culture and grown as a monolayer in a 
humidified incubator (95% air, 5% CO2) at 37 °C in a Petri dish containing Dulbecco’s 
modified Eagle’s medium (DMEM, Sigma) supplemented with 1% 
penicillin/streptomycin and 10% heat-inactivated fetal bovine serum (FBS, Gibco). 5 × 
103 cells were seeded in each well of a 96-well culture plate and incubated for 24 h. The 
medium of each well was then replaced with 90 µL of fresh DMEM containing 10% 
FBS and 10 µL of a PEG-PION dispersion in PBS at selected concentrations. Control 
experiments were carried out using PBS instead of the PEG-PION dispersion. The 
culture plate was returned to the incubator and incubated for 24 h. After this incubation 
period, the medium was removed and the cells were rinsed five times with PBS (pH 7.4). 
The viability of the cells was evaluated by means of the colorimetric WST assay using 
Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) according to the manufacturer’s 
instructions. Briefly, 10 µL of WST-8 reagent was added to each well and incubated for 
2 h at 37 °C. The absorbance at 450 nm was measured by a Varioscan Flash plate reader 
(Thermo Fisher Scientific Inc., UK). The results were expressed as a percentage relative 
to the control. 
 
2.5. In vivo study 
All procedures involving animal care were approved by the Animal Ethics 
Committee of the University of Tsukuba, and were conducted according to the 
Guidelines for Animal Experimentation of the University of Tsukuba. The blood 
circulation behavior of PEG-PION4 was examined in normal ICR mice (female; age, 7 
weeks; weight, 25-29 g). The PEG-PION4 dispersion in physiological saline was 
administered intravenously to mice at a dose of 84 mg Fe kg-1 mouse, and blood was 
collected from the heart after defined time periods (0.05, 4, 8, 24, and 48 h). Control 
experiments were carried out with the intravenous administration of physiological saline 
instead of the PEG-PION4 dispersion. The Fe concentrations in the collected blood 
samples were determined by ICP-MS. The in vivo distribution of PEG-PION4 was 
assessed in C-26 tumor-bearing BALB/c mice 14 days after the implantation of C-26 
cells (1 × 106 cells/200 µL per mouse) when the mean tumor volume was >100 mm3 
(female; age, 7 weeks; weight, 23-27 g). The PEG-PION4 dispersion in physiological 
saline was administered intravenously to the mice at a dose of 84 mg Fe kg-1 mouse. 
Control experiments were carried out with intravenous administration of physiological 
saline instead of the PEG-PION4 dispersion. For analysis, the mice were sacrificed 
using the approved method of dislocation of the neck with anesthesia after defined time 
periods (0.05, 4, 8, 24, 48, and 96 h), after which they were perfused with physiological 
saline. Major tissues (tumor, heart, lung, kidney, spleen, and liver) were excised and 
lyophilized. The tissue samples were dissolved in HNO3/H2O2 (3:1 (v/v)) and 
evaporated to dryness. The residues were redissolved in 0.5 mol L-1 HNO3, and the Fe 
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content in each tissue sample was determined by ICP-MS measurements. 
 
2.6. In vivo MRI imaging 
	 In vivo MRI imaging was carried out on C-26 tumor-bearing mice. PEG-PIONs were 
injected intravenously into mice at a dose of 2.1 mg per mouse on the basis of Fe. After 
24 h, T2-weighted FSE imaging was performed. The mice were anesthetized using 1% 
isoflurane admixed with 50% N2O and 50% O2 during imaging. 
 
2.7. Prussian blue staining 
The tumor sample excised 24 h after the intravenous administration of PEG-PION4 
was fixed in 10% paraformaldehyde, embedded in paraffin, and cut in slices 2 µm in 
thickness. For Prussian blue staining, the slides were incubated for up to 20 min at room 
temperature with fresh 2% potassium ferrocyanide in water mixed with an equal volume 
of 1% hydrochloric acid. Slides were washed, counterstained with nuclear fast red 
(Kernechtrot stain solution, Muto Pure Chemicals, Japan), and mounted and then 
photographed with a microscope (BX50F, Olympus Optical Co. Ltd., Tokyo, Japan). 
 
 
3. Results and discussion 
 
3.1. Preparation of PEG-PIONs 
Several methodologies have been established for the preparation of IONs, such as 
coprecipitation, thermal decomposition, and the hydrothermal method [40]. Among 
these, coprecipitation of iron salts under alkali conditions is commonly employed, 
because of its ease of operation and amenable scale-up. In this study, we performed the 
alkali coprecipitation of iron salts in the presence of PEG-b-PVBP to prepare IONs 
coated with PEG-b-PVBP (PEG-PIONs, Scheme 1b). The preparation of metal (oxide) 
nanoparticles in a liquid phase containing a stabilizer has been shown to be useful for 
controlling the particle size and the density of the surface-bound stabilizer 
[12,20,25,41-43]. Aqueous mixtures of iron salts containing various amounts of 
PEG-b-PVBP were prepared, and NH4OH solution was subsequently added to the 
mixtures. The color of the solutions changed from yellow to dark red-brown 
immediately after the addition of NH4OH, indicating the generation of IONs. After 
stirring for 2 h at room temperature, the resulting mixture was dialyzed against 
deionized water to neutralize it and then purified by ultrafiltration until the unbound 
PEG-b-PVBP was completely removed. The removal of the unbound PEG-b-PVBP 
could be monitored by the absorption peak of the filtrate (around 210−250 nm), which 
corresponds to the benzyl moiety of PEG-b-PVBP. During the purification process, no 
agglomeration was occurred in any of the samples. 
 
3.2. Characterization of PEG-PIONs 
The core size of PEG-PIONs was visually confirmed by TEM measurements. For 
instance, Fig. 1 shows a typical TEM image of PEG-PION1. The number-averaged 
diameters (dn) of the PEG-PIONs were determined by TEM image analyses, and the 
results are summarized in Table 1. In general, the size of IONs generated by the 
coprecipitation method in the presence of the stabilizer depends on the feed ratio 
between the stabilizer and the iron salts [41-43]. The core sizes of the PEG-PIONs 
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prepared in this study, however, were almost identical (≈ 7.7 nm) regardless of the feed 
ratio of PEG-b-PVBP to iron salts. Before the addition of ammonia to the mixture of 
PEG-b-PVBP and iron salt solution, the formation of micelle-like aggregates 
(hydrodynamic diameter ≈ 30 nm) was observed through DLS measurements. These 
aggregates presumably act as a “template” leading to the generation of IONs of almost 
the same size. Powder XRD analyses were performed to confirm the crystalline 
properties of the PEG-PIONs (data not shown). The obtained results showed 
characteristic diffraction peaks (2θ = 30.2°, 35.5°, 43.2°, 53.8°, and 57.2°) similar to 
those of maghemite (γ-Fe2O3) and magnetite (Fe3O4) [19,25,29,42,43]. The dark 
red-brown color of the PEG-PION dispersions strongly indicated that the ION core of 
the PEG-PIONs was mainly in the γ-Fe2O3 structure. 
To characterize the obtained particles, we carried out FT-IR measurements (Fig. S1 in 
supporting information). The FT-IR spectra of the PEG-PIONs strongly suggest the 
existence of PEG-b-PVBP on the PEG-PIONs surfaces, showing the characteristic 
peaks of PEG-b-PVBP around 1456 cm-1 (ν(C=C)), 1350 cm-1 (ν(C=C)), 1247 cm-1 
(ν(P=O)), 1110 cm-1 (ν(P–O)), 946 cm-1 (ν(P–O)), and 839 cm-1 (δ(C–H)). The 
existence of PEG-b-PVBP on the PEG-PIONs surface was further confirmed by the zeta 
potential measurements (Fig. 2a). For the bare IONs, the zeta potential varied 
significantly from highly positive (≈ +35 mV) to negative (≈ -35 mV) with the 
increasing pH of the medium (from pH 2 to 11). On the contrary, the PEG-PIONs 
showed a relatively small change in the zeta potential compared to the bare iron oxide 
particles over the same pH range. In addition, the absolute values of the zeta potentials 
of the PEG-PIONs were significantly smaller than those of the bare IONs. In particular, 
the zeta potentials of PEG-PION3 and PEG-PION4 were close to 0 mV regardless of 
the pH of the medium. These results strongly suggest that the PVBP segment of 
PEG-b-PVBP binds to the iron oxide surface, allowing the formation of a PEG brush 
layer, as illustrated in Scheme 1b. 
The amounts of PEG-b-PVBP adsorbed onto the PEG-PION surfaces were examined 
by TGA. Fig. S2 in supporting information shows the TGA thermograms of free 
PEG-b-PVBP and PEG-PIONs. The free PEG-b-PVBP revealed characteristic two-step 
thermal decomposition behavior (Fig. S2a). The distinct weight losses observed around 
370−400 °C and 460−520 °C correspond to the thermal decomposition of the PEG 
segment and polystyrene moiety, respectively. Accordingly, the resulting mass observed 
at over 550 °C (ca. 28%) can be regarded as corresponding to the phosphonate moieties. 
For the PEG-PIONs, the degree of weight loss increased with an increase in the 
[PEG-b-PVBP]/[iron salts] feed ratio (Fig. S2b−e). The surface PEG-chain density on 
each PEG-PION sample was estimated from the percentage weight loss at 650 °C 
(WL650) and dn of each ION core (Table 1), under the following assumptions: (i) the 
mass remaining at over 550 °C corresponds to the fraction of ION core and P2O5 (the 
major product of organic phosphonates by thermal decomposition [44]); (ii) the density 
of the ION core is 4.89 g·cm-3 (as γ-Fe2O3) [45]; and (iii) all PEG-b-PVBP chains are 
anchored onto the ION core surface as a single layer. As depicted in Fig. 2b, the surface 
PEG-chain density on the PEG-PIONs gradually increased with an increase in the 
[PEG-b-PVBP]/[iron salts] feed ratio, and reached a plateau above [PEG-b-PVBP]/[iron 
salts] = 0.35. This is consistent with the results of the zeta potential measurements of 
PEG-PIONs. The maximum surface PEG-chain density on the PEG-PIONs prepared 
here was ≈ 0.8 chains·nm-2, which is significantly higher than found for previous 
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PEGylated IONs (below 0.4 chains·nm-2) [20,22,25-30]. 
 
3.3. Dispersion stability of PEG-PIONs 
As mentioned in the Introduction, the dispersion stability of the IONs under 
physiological conditions is crucial for their systemic administration. The dispersion 
stability of PEG-PIONs in PBS was assessed by DLS. For PEG-PION1 and 
PEG-PION2, the particles flocculated just after their dispersion in PBS, and obvious 
precipitation was observed within 1 h (data not shown). On the contrary, PEG-PION3 
and PEG-PION4 dispersed stably into PBS and showed no significant changes in their 
hydrodynamic diameters over a period of more than two weeks (Fig. 3a). These results 
indicate that the surface PEG-chain density greatly influences the dispersion stability of 
PEG-PIONs, as reported previously [13]. Phosphate salts from PBS are known to bind 
to the metal oxide surface and/or displace with the chemisorbed stabilizer, resulting in a 
decrease in the dispersion stability [37,47]. Riffle et al. reported that the hydrodynamic 
diameter of IONs covered with monophosphonate-functionalized PEG gradually 
increased in PBS over 24 h [37]. More recently, we showed that the 
monophosphonate-functionalized PEG adsorbed onto an Y2O3 surface easily displaced 
with phosphate salts in PBS [40]. Both PEG-PION3 and PEG-PION4 could maintain 
their dispersion in PBS without any change in their hydrodynamic diameters over a 
period of two weeks. This long-term dispersion stability in the presence of phosphate 
salts is presumably due to the multipoint anchoring of the PVBP segment of 
PEG-b-PVBP onto the ION core surface. Such multipoint anchoring of the PVBP 
segment might make it difficult for the PEG-b-PVBP to be replaced by the phosphate 
salts in PBS. In addition, the hydrophobic nature of the polystyrene backbone of the 
PVBP segment might enhance the stability of the PEG brush layer on the ION surface. 
The excellent dispersion stabilities of PEG-PION3 and PEG-PION4 were also 
confirmed in the serum-containing medium. These samples formed stable dispersions in 
10% FBS containing PBS without any change in their hydrodynamic diameters for over 
one week (Fig. 3b). It should be noted that the hydrodynamic diameters of PEG-PION3 
and PEG-PION4 were almost identical to those in the absence of FBS (Fig. 3a). This 
strongly suggests that both PEG-PION3 and PEG-PION4 possess excellent 
anti-biofouling surface properties. 
 
3.4. Cytotoxicity of PEG-PIONs 
  To assess the potential toxicity of PEG-PION3 and PEG-PION4, a WST assay was 
performed using C-26 cells. The results shown in Fig. S3 (in Supporting Information) 
indicate that both PEG-PION3 and PEG-PION4 have little effect on cell viability even 
at high concentrations. The amount of Fe at the highest concentration was ≈ 30 mg Fe 
mL-1 which was higher than that of typical ION-based MR imaging agents for mice 
(1−15 mg Fe mL-1). Thus, we concluded that PEG-PION3 and PEG-PION4 have 
minimal toxicity. 
 
3.5. Biodistribution of PEG-PIONs 
In the previous section, we revealed that PEG-PION3 and PEG-PION4 possess an 
excellent anti-biofouling properties and high dispersion stabilities under physiological 
conditions. It is also noteworthy that PEG-PION4 maintained its hydrodynamic size 
below 50 nm for over one week, even in the presence of serum proteins. This retention 
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of a consistent particle size is important from the viewpoint of improving blood 
circulation behavior, since larger nanoparticle sizes facilitate phagolytic clearance [3-5]. 
From the results obtained, we anticipated that PEG-PION4 could circumvent 
recognition by RES and prolong blood circulation. 
The blood circulation behavior of PEG-PION4 in mice was assessed by following the 
variation in the Fe content in the blood after intravenous administration (84 mg Fe kg-1 
of dose). The results are expressed as the mean percentage of injected dose (% ID) mL-1 
blood, and are plotted against post-injection time (Fig. 4a). As anticipated, PEG-PION4 
showed stable circulation in the bloodstream; 24 h after intravenous administration, 
14.1 % ID mL-1 of PEG-PION4 remained in the blood. In contrast, the commercial 
Ferucarbotran (Resovist) showed a very short blood circulation time (< 5 % ID mL-1 
blood 3 h after intravenous administration) under the same administration conditions, 
presumably because of rapid clearance by RES. 
The accumulation behavior of PEG-PION4 in the major organs (heart, lung, kidney, 
spleen, liver, and tumor) after intravenous administration to tumor-bearing mice was 
assessed by ICP-MS (Fig. 4b). Interestingly, although PEG-PION4 has no 
tumor-targeting ligand molecules the ICP-MS results revealed continuous accumulation 
of PEG-PION4 in the tumor after intravenous administration. More than 15 % ID g-1 
tumor of PEG-PION4 accumulation was confirmed from 8 h after intravenous 
administration, and this could be detected by in vivo MR imaging. The T2-weighted 
image at 24 h after intravenous administration showed that the MR signal intensity of 
the tumor decreased significantly, allowing clear identification of the tumor (Fig. 5, 
tumor site indicated by the arrow). To our knowledge, there have been only a few 
reports on the effective accumulation of polymer-coated IONs (more than 15 % ID g-1 
tumor) through systemic administration without the aid of any targeting ligand 
[29,30,32]. The distribution of PEG-PION4 in the tumor tissue was visualized by 
Prussian blue staining. As shown in Fig. 6, PEG-PION4 was distributed around the 
tumor blood vessels to the outside through the leaky from the tumor vascular walls 
(indicated by the arrow), suggesting that PEG-PION4 accumulated in the tumor tissue 
through the enhanced permeability and retention (EPR) effect [47]. The small 
hydrodynamic size, neutral surface charge, and excellent anti-biofouling surface 
properties of PEG-PION4 should make its EPR-effect-mediated tumor-specific 
accumulation feasible. 
  Significant accumulation of PEG-PION4 in normal tissues such as the liver and 
spleen was also confirmed by ICP-MS analyses. Its accumulation in the liver peaked at 
24 h after injection (15.8 % ID g-1 tissue). However, it is interesting to note that the 
accumulated PEG-PION4 then started to be washed out, as was confirmed by ICP-MS. 
Eventually, the accumulated level of PEG-PION4 in the liver was reduced to 4.8 % ID 
g-1 tissue at 96 h after injection. A similar accumulation/clearance tendency was also 
confirmed in other normal tissues including the spleen. On the contrary, for the tumor 
tissue, the accumulated PEG-PION4 showed only a moderate clearance, and 13.4 % ID 
g-1 tissue of PEG-PION4 still remained even at 96 h after injection. This is presumably 
due to the defective and/or suppressed lymphatic drainage in the tumor [47]. The 
metabolic difference in PEG-PION4 between normal and tumor tissues observed here is 
useful not only for enhancing its selective localization in tumor tissue, but also for 
promoting the safety of its administration, since long-term accumulation of inorganic 
nanoparticles in the living body often causes unexpected injury [48-50]. Although the 
10 
 
detailed mechanism is not clear at this stage, we believe that the favorable metabolic 
properties of PEG-PION4 are closely related to the size and surface properties of these 
nanoparticles.  
 
 
4. Conclusions 
  In this study, we have demonstrated the preparation of PEGylated IONs 
(PEG-PIONs) by the simple coprecipitation reaction of iron salts in the presence of 
PEG-b-PVBP. In our approach, PEG-b-PVBP served as a surface coating and was 
robustly anchored to the ION surface via multipoint chemical bond formation between 
the ION surface and the phosphonate groups in the PVBP segment of PEG-b-PVBP. 
PEG-PIONs prepared under optimal conditions (PEG-PION4) showed a sufficiently 
high surface PEG-chain density (≈ 0.8 chains·nm-2) and small hydrodynamic diameter 
(< 50 nm). Furthermore, PEG-PION4 could be dispersed in 10% serum containing PBS 
without any change in its hydrodynamic diameter over a period of one week, indicating 
its high dispersion stability under physiological conditions, as well as its excellent 
anti-biofouling properties. These features of PEG-PION4 prolonged its blood 
circulation time and facilitated its EPR-effect-mediated tumor accumulation after 
intravenous administration to tumor-bearing mice. The majority of the PEG-PION4 
accumulated in normal tissues (such as the liver and spleen) was smoothly eliminated 
up to 96 h after administration, whereas most of the PEG-PION4 accumulated in the 
tumor remained there even at 96 h after administration, and 13.4 % ID g-1 tumor of 
PEG-PION4 was detected by ICP-MS analysis. This metabolic difference in 
PEG-PION4 between normal and tumor tissues is thought to enhance the selectivity of 
its localization in tumor tissue. Our approach would be beneficial for developing 
tumor-targeted and safe ION-based biomedical devices. Finally, we wish to emphasize 
that the molecular design of PEG-b-PVBP is rational for the construction of 
PEGylated-ION-based biomedical devices that remain intact under harsh biological 
condition over long periods of time, and also that PEG-b-PVBP can be applied for the 
effective surface PEGylation of other nanoparticles such as metal oxides and ceramics. 
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FIGURE CAPTIONS 
Fig. 1  TEM image of PEG-PION1. Inset is size distribution of PEG-PION1 obtained 
by TEM analysis. 
Fig. 2   a) Zeta potential vs. pH plot for bare IONs (solid square), PEG-PION1 (open 
triangle), PEG-PION2 (solid triangle), PEG-PION3 (open circle), and 
PEG-PION4 (solid circle). Data expressed are means of triplicate 
measurements (± S.D.). b) Change in the surface PEG chain density on 
PEG-PIONs with (PEG-b-PVBP)/(iron salts) feed ratio. 
Fig. 3   Hydrodynamic diameters of PEG-PION3 (open circle) and PEG-PION4 (solid 
circle) upon incubation in (a) PBS, (b) 10 % of FBS containing PBS at room 
temperature. 
Fig. 4 a) Blood circulation behavior of PEG-PION4 (open circle), commercial 
ferucarbotran (solid circle) after intravenous administration to ICR mice 
(Dose: 84 mg Fe kg-1 mouse, N= 5). The levels of Fe in blood are shown as 
the mean percentage of injected dose (% ID) mL-1 blood at each time period. 
b) Biodistribution of PEG-PION4 after intravenous administration to C-26 
tumor bearing mice (Dose: 84 mg Fe kg-1 mouse, N = 5). The levels of Fe in 
tumor (open circle), liver (solid circle), spleen (open triangle), kidney (solid 
triangle), lung (open square) and heart (solid square) are shown as the mean 
percentage of injected dose (% ID) g-1 tissue at each time period. 
Fig. 5 T2-weightened images of C-26 tumor bearing mice at 24 h post-injection of 84 
mg Fe kg-1 of PEG-PION4 (a) and control (b). The arrow denotes tumor site. 
Fig. 6  Photograph of C-26 xenograft tumor tissue stained by Prussian blue. The blue 
area indicates the existence of PEG-PION4. 
 
Scheme 1 (a) Chemical structure of PEG-b-PVBP. (b) Schematic illustration of 
suspected structure of PEG-PIONs prepared in this study. 
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S-1. Materials 
All reagents were commercially available and were used as received. PEG-b-PVBP 
was synthesized by the two-step side-chain conversion of the PEG-poly 
(4-chloromethylstyrene) block copolymer, which was prepared by our previous method 
[S1]. The quantitative conversion of the chloromethyl side chains into phosphonic acid 
groups was confirmed by both 
1
H- and 
31
P-NMR spectroscopy. The number-averaged 
molecular weight (Mn) of the PEG segment was 5,000 g mol
-1
, and the degree of 
polymerization of the PVBP segment (n) was 15. Details of the synthesis of 
PEG-b-PVBP are reported elsewhere [S2]. Murine colon adenocarcinoma 26 (C-26) 
cells were obtained from RIKEN BioResource Center. ICR mice (female; age, 7 weeks; 
weight, 25−29 g) and BALB/c mice (female; age, 5 weeks; weight, 17−22 g) were 
purchased from Charles River Japan Inc. Deionized water (>18.1 M cm) purified with 
a Milli-Q instrument (Millipore, Billerica, MA) was used for all of the experiments. 
 
 
S-2. Measurements 
UV-Vis measurements were conducted on a UV2400 PC spectrophotometer 
(Shimadzu, Kyoto, Japan), and FT-IR measurements on an FT/IR-300 spectrometer 
(JASCO, Tokyo, Japan). FT-IR spectra were collected by the KBr pellet method at a 
resolution of 4 cm
-1
 with 128 scans. DLS and zeta potential measurements were carried 
out using a Zetasizer Nano ZS (Malvern Instruments, Ltd., U.K.) equipped with a 
10-mW He-Ne laser ( = 633 nm), which produces vertically polarized incident beams 
at a detection angle of 173°. Thermogravimetric analysis (TGA) was performed using 
an SII EXTRA6000 DSC/TG/DTA thermal analyzer (Seiko Instrument Inc., Chiba, 
Japan). Lyophilized samples were first held at 140 °C for 20 min to eliminate moisture, 
and then the temperature was ramped at a rate of 10 °C min
-1
 to a maximum of 900 °C. 
All TGA experiments were performed under an Ar flow (200 mL min
-1
) to minimize 
sample oxidation. TEM images were obtained using a HITACHI H-800 transmission 
electron microscope (Hitachi Ltd., Tokyo, Japan) at an accelerating voltage of 80 kV. 
For TEM sample preparation, ION dispersions were diluted and deposited on a 
carbon-coated copper grid and allowed to air-dry. The obtained images were analyzed 
using Image J software (NIH). Powder X-ray diffraction measurements were performed 
on an RINT-2200 X-ray diffractometer (RIGAKU, Tokyo, Japan) with CuK radiation. 
ICP-MS measurements were performed on an ELAN DRC-e ICP-MS spectrometer 
(Perkin-Elmer Sciex, UK). In vivo MRI images were obtained using a 3-T Signa HDx 
whole-body MRI scanner (GE Healthcare, Milwaukee, WI). A body coil was used to 
transmit radiofrequency (RF) pulses, and a 3-turn solenoid coil dedicated for animal 
experiments was used to receive the signal. For the T2-weighted fast spin-echo (FSE) 
images of living mice, the following parameters were applied: repetition time (TR) = 
4000 ms, echo time (TE) = 69 ms, flip angle (FA) = 90°, number of excitations (NEX) = 
2. The images were obtained with a field of view (FOV) of 6 × 3 cm, a 256 × 160 
matrix, and a 1-mm slice thickness (THK). 
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S-3. Characterization of PEG-PION 
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Fig. S1 FT-IR spectra of (a) PEG-b-PVBP, (b) PEG-PION1, (c) PEG-PION2, (d) 
PEG-PION3, and (e) PEG-PION4. 
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Fig. S2 TG thermograms of (a) PEG-b-PVBP, (b) PEG-PION1, (c) PEG-PION2, (d) 
PEG-PION3, and (e) PEG-PION4. 
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Fig. S3 Viability of C-26 cells after the 24-h incubation with PEG-PION3 (open circle) 
and PEG-PION4 (solid circle) at various concentrations. 
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